WallStSmart

CME Group Inc (CME)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CME Group Inc generates 192% more annual revenue ($6.74B vs $2.31B). CME leads profitability with a 63.3% profit margin vs -9.0%. CME earns a higher WallStSmart Score of 65/100 (C+).

CME

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 4.3Quality: 5.5
Piotroski: 1/9

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CME6 strengths · Avg: 9.0/10
Profit MarginProfitability
63.3%10/10

Keeps 63 of every $100 in revenue as profit

Operating MarginProfitability
69.8%10/10

Strong operational efficiency at 69.8%

Market CapQuality
$101.91B9/10

Large-cap with strong market position

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
21.3%8/10

Earnings expanding 21.3% YoY

Free Cash FlowQuality
$1.24B8/10

Generating 1.2B in free cash flow

NTRA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.8%10/10

Revenue surging 39.8% year-over-year

Areas to Watch

CME2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
4.862/10

Expensive relative to growth rate

NTRA4 concerns · Avg: 2.8/10
Price/BookValuation
15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability
-9.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CME

The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bear Case : CME

The primary concerns for CME are Piotroski F-Score, PEG Ratio.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

CME profiles as a mature stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

CME generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

CME scores higher overall (65/100 vs 31/100), backed by strong 63.3% margins and 14.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CME Group Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.

Visit Website →

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?